More News! 17 Jan 2017 Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors AiCuris’ candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, […] January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 German Antibody for Cancer Diagnostics catches an Australian Eye Wilex is selling Telix Pharmaceuticals its radiolabeled antibody for cancer applications, Redectane, to focus on the development of ADCs instead. The Australian Telix Pharmaceuticals has closed a license agreement with Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 Merck partners with Big Data Unicorn to help Cancer Patients Merck will use Palantir’s big data software to improve drug development and patient services, starting with cancer treatments. Merck will step up its data analytics capabilities in partnership with Palantir. The US company, co-founded by PayPal billionaire Peter Thiel, provides data integration and analysis software that Merck plans to use to improve patient care and […] January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 12 Jan 2017 German Microscopy Tech raises funds to take over Imaging in Biology Luxendo has raised €8M to start international sales of its unique microscopy technology aiming to take over confocal microscopes in biology research. Luxendo, a spin-out from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, has closed its Series A fundraising round led by Life Science Partners (LSP), one of the best European biotech VCs. The total €8M raised will be […] January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic antibodies for big names like Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche and Janssen. The company is now adding type 2 diabetes to its long list of indications; bimagrumab will start Phase […] January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […] January 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […] January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2017 Top European VC and CRO fund Young Metabolic Disease Biotech Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company has now raised €8M in Series A, led by Scottish biotech VC Epidarex Capital. Among the […] January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2017 German Immuno-Oncology Biotech partners up with Biotech Giant Amgen Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […] January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 Cold Sore Cure Company enters the Antibiotic Resistance fight AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 New German Immuno-oncology Partnership takes on Solid Tumors TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email